Welcome to our dedicated page for Amylyx Pharmaceuticals SEC filings (Ticker: AMLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amylyx Pharmaceuticals, Inc. filings document a clinical-stage biotechnology issuer developing investigational therapies in endocrine conditions and neurodegenerative diseases. Its 8-K reports furnish quarterly and annual financial results, corporate presentations and material-event disclosures tied to programs such as avexitide for post-bariatric hypoglycemia, AMX0318 and AMX0035.
Proxy and material-event filings describe governance, executive compensation, shareholder voting matters, common-stock registration on the Nasdaq Global Select Market, capital-structure matters, material agreements and program decisions. These records also capture collaboration economics, development-candidate selections, expanded pipeline disclosures and formal updates to clinical programs.
Amylyx Pharmaceuticals, Inc. insider Gina Mazzariello, Chief Legal Officer, reported two open-market sales of common stock. On July 9, 2026, she sold 15,000 shares at a weighted average price of $18.3164 per share, and on July 10, 2026 she sold another 15,000 shares at a weighted average price of $17.6081 per share. The filing states that these sales were effected pursuant to a Rule 10b5-1 trading plan adopted on April 9, 2026. Following the transactions, she holds 179,090 shares of Amylyx Pharmaceuticals common stock directly.
Amylyx Pharmaceuticals director Bernhardt G. Zeiher received a grant of 24,372 stock options. These options give the right to buy 24,372 shares of Amylyx common stock at an exercise price of $14.31 per share and expire on June 3, 2036.
According to the terms, the options vest in full on the earlier of June 4, 2027 or the date of the next annual meeting, as long as the director remains in continuous service with the company through that vesting date. After this grant, the director holds 24,372 derivative securities directly.
Amylyx Pharmaceuticals director Karen Firestone received a grant of stock options covering 24,372 shares of common stock at an exercise price of $14.31 per share. These options vest in full on the earlier of June 4, 2027 or the next annual meeting, provided she remains in continuous service, and bring her directly held option position reported in this filing to 24,372 shares.
Amylyx Pharmaceuticals director Daphne Quimi received a stock option grant covering 24,372 shares of Common Stock. The option has an exercise price of $14.31 per share and expires on June 3, 2036. It vests in full on the earlier of June 4, 2027 or the next annual meeting, subject to her continuous service, and represents her entire reported option position in this filing.
Amylyx Pharmaceuticals director George M. Milne Jr. received a grant of stock options covering 24,372 shares of common stock. The options have an exercise price of $14.31 per share and expire on June 3, 2036. They vest in full on the earlier of June 4, 2027 or the next annual meeting, as long as he continues serving the company.
Amylyx Pharmaceuticals director Paul R. Fonteyne received a grant of stock options covering 24,372 shares of common stock. The options have an exercise price of $14.31 per share and were awarded at no cost to him as compensation.
These options vest in full on the earlier of June 4, 2027 or the date of the next annual meeting, as long as he continues serving the company through that date. After this grant, he holds 24,372 stock options directly.
Amylyx Pharmaceuticals, Inc. reported the results of its annual stockholder meeting. Stockholders elected George Mclean Milne Jr., Ph.D. and Paul Fonteyne as Class II directors to serve until the 2029 annual meeting, with each nominee receiving more than 76 million votes for.
Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 102,036,295 votes for and minimal opposition. In a non-binding advisory vote, stockholders approved the compensation of the company’s named executive officers, with 77,534,824 votes for and 13,490,653 against.
Amylyx Pharmaceuticals director Karen Firestone made an open-market purchase of the company’s Common Stock. On May 21, 2026, she bought 3,800 shares at a price of $13.51 per share. Following this transaction, she directly owns 66,900 shares of Amylyx common stock.
Amylyx Pharmaceuticals ownership update: Perceptive Life Sciences Master Fund, Ltd. directly holds 8,284,882 shares of Common Stock, representing 7.5% of the class based on 111,186,317 shares outstanding as of April 27, 2026. Perceptive Advisors LLC is the investment manager and Joseph Edelman is the managing member; all three Reporting Persons report shared voting and dispositive power over the same 8,284,882 shares.